<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124392</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000214</org_study_id>
    <nct_id>NCT05124392</nct_id>
  </id_info>
  <brief_title>Biomarker Profiling in Individuals at Risk for Prion Disease</brief_title>
  <official_title>Biomarker Profiling in Individuals at Risk for Prion Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Broad Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research to identify biomarkers in individuals who are at-risk for familial&#xD;
      prion disease. We hope to use these biomarkers to predict timing of disease onset in&#xD;
      pre-symptomatic individuals and to guide the direction of future clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to measure biomarkers longitudinally in individuals at risk of developing&#xD;
      genetic prion disease to identify clinical assays and molecular markers that: can inform our&#xD;
      understanding of pre-clinical pathology, predict timing of disease onset in pre-symptomatic&#xD;
      individuals, and enable development and evaluation of novel treatment efficacy in&#xD;
      pre-symptomatic or early symptomatic individuals.&#xD;
&#xD;
      Participation in the study involves annual visits to the clinic site in Charlestown, MA.&#xD;
      Study visits include: a medical exam, blood draws, cognitive tests and questionnaires, spinal&#xD;
      fluid collection, and (optional) MRI.&#xD;
&#xD;
      Travel support and stipend is provided for interested individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>CSF YKL40</measure>
    <time_frame>1 year</time_frame>
    <description>Levels of YKL40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF Tau</measure>
    <time_frame>1 year</time_frame>
    <description>Levels of Tau</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF Nfl</measure>
    <time_frame>1 year</time_frame>
    <description>Levels of Nfl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF GFAP</measure>
    <time_frame>1 year</time_frame>
    <description>Levels of GFAP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF Prion protein</measure>
    <time_frame>1 year</time_frame>
    <description>Levels of Prion protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CSF Prion biomarkers</measure>
    <time_frame>1 year</time_frame>
    <description>RT-QuIC levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognition</measure>
    <time_frame>1 year</time_frame>
    <description>NIH Toolbox measures of cognition</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>CJD (Creutzfeldt Jakob Disease)</condition>
  <condition>Prion Diseases</condition>
  <condition>GSS</condition>
  <condition>FFI</condition>
  <condition>Familial Fatal Insomnia</condition>
  <arm_group>
    <arm_group_label>Individuals with a family history of Prion disease</arm_group_label>
    <description>Individuals with a family history of Prion disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and Cerebral Spinal Fluid for biomarker quantification&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        80 people ages 18-85 with history of genetic prion disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 - 85,&#xD;
&#xD;
          2. One of the following:&#xD;
&#xD;
               1. Known carrier of pathogenic PRNP mutation&#xD;
&#xD;
               2. History of probable or definite prion disease in biological parent and other&#xD;
                  family members&#xD;
&#xD;
          3. Medically safe to undergo blood draw, lumbar puncture and cognitive testing,&#xD;
&#xD;
          4. Adequate visual and auditory acuity to complete cognitive testing,&#xD;
&#xD;
          5. Fluent in English,&#xD;
&#xD;
          6. At least 5 years of education,&#xD;
&#xD;
          7. Capable of providing informed consent and following study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any CNS disease other than asymptomatic or early prion disease, such as clinical&#xD;
             stroke, brain tumor, multiple sclerosis, significant head trauma with persistent&#xD;
             neurological or neurocognitive deficits, Alzheimer's disease, Parkinson's disease,&#xD;
             frontotemporal lobar degeneration or other known neurodegenerative disease,&#xD;
&#xD;
          2. History of alcohol or other substance abuse or dependence within the past two years,&#xD;
&#xD;
          3. Any significant systemic illness or unstable medical condition or pregnancy that could&#xD;
             represent safety risk or affect participation in the study,&#xD;
&#xD;
          4. Coagulopathy or anti-coagulant therapy (such as Coumadin) increasing the risk for&#xD;
             phlebotomy or lumbar puncture resulting in PT/PTT and INR within 1.5 standard&#xD;
             deviation over the upper normal limit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shona Allen</last_name>
    <phone>617-726-0928</phone>
    <email>sallen16@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arianna Tidball</last_name>
    <email>atidball@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alzheimer's Clinical and Translational Research Unit</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gerber</last_name>
      <phone>617-724-1992</phone>
      <email>jgerber2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Steven E Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven E Arnold</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prion Diseases</mesh_term>
    <mesh_term>Creutzfeldt-Jakob Syndrome</mesh_term>
    <mesh_term>Insomnia, Fatal Familial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

